AtaiBeckley Inc.
AtaiBeckley Inc. is a U.S.-based biopharmaceutical company focused on developing psychedelic and non-psychedelic product candidates for mental health and related indications. Through its wholly owned subsidiary Nualtis, it also operates a drug-delivery business that develops and manufactures novel oral thin film products and provides contract research and manufacturing services.
Fiscal year 2025 · change from previous year
Development 2024–2025
Business
Share of revenuePsychedelic and non-psychedelic compounds being developed for future commercialization.
Licenses of Nualtis proprietary oral thin film technologies to customers.
Research and development work performed for customers under service agreements.
Development and manufacturing services for oral thin film pharmaceutical products.
Products
Reported · share of revenue- Research and Development Services Revenue95.1 %
- License4.9 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
The company serves pharmaceutical and biotech customers that want to use oral thin film drug-delivery technology in their own products, as well as partners that license Nualtis technology for development programs. It also depends on future commercialization partners and regulators for its core product candidates, which are still in clinical development. Revenue today is tied mainly to service and license arrangements rather than product sales.
Buy rights to Nualtis proprietary oral thin film technology for use in their products.
Engage Nualtis for research and development services tied to drug-delivery programs.
Potential partners that would commercialize approved product candidates if development succeeds.
Work with the company on preclinical and clinical programs for product candidates.
Strategy
The company’s strategy is to advance its product candidates through preclinical and clinical development and, if successful, move them toward regulatory approval and commercialization. In parallel, it uses Nualtis to generate license and R&D service revenue while building a proprietary oral thin film platform that can support both third-party customers and its own pipeline. It also relies on non-dilutive funding sources and strategic investments to support development activities.
Regulatory approval is required before core product candidates can generate product revenue.
License and R&D agreements provide current revenue while the core pipeline remains in development.
Development-stage operations require external capital before product commercialization.
Geography
AtaiBeckley is headquartered in the United States, but its operating footprint is international through research, tax-credit, and development activities. The company specifically cites research and development tax credits in Australia, Canada, and the United Kingdom, indicating a multi-country development structure. Geography matters because clinical development, manufacturing support, and funding sources are spread across several jurisdictions.
Risks
The company faces the classic risks of a clinical-stage biopharmaceutical business: uncertain trial outcomes, regulatory approval risk, and the possibility that product candidates never reach commercialization. Its current revenue base is limited and depends on customer demand for Nualtis services and license arrangements, while development spending and capital needs remain substantial. Fair value investments, digital assets, and contingent financing structures also add volatility to reported results and liquidity.
Product candidates are still in preclinical and clinical development, so outcomes are uncertain.
Exposure: Core pipeline
No product revenue is expected until candidates receive regulatory approval, if ever.
Exposure: Psychedelic and non-psychedelic candidates
License and R&D revenue comes from a limited set of agreements and can fluctuate.
Exposure: Nualtis
Development-stage operations require ongoing external capital before commercialization.
Exposure: Corporate funding
Fair value changes in COMPASS and Bitcoin can affect reported results and liquidity.
Exposure: Non-operating assets
Accounting
Judgemental itemsCurrent revenue is driven by service and license contracts, so timing depends on contract milestones and performance obligations.
Impact: Affects quarterly revenue volatility and comparability
COMPASS holdings, digital assets, contingent warrants, and derivative liabilities are remeasured at fair value.
Impact: Can create large non-operating gains or losses
Employee and executive compensation includes equity awards, which are significant in development-stage biotech.
Impact: Raises operating expenses without cash outflow
Clinical, preclinical, and manufacturing costs are expensed as incurred.
Impact: Keeps reported earnings negative until commercialization
Similar listed companies
Publicly listed companies with a comparable business focus.
Atai Beckley N.V.
Pharmaceutical Preparations
Atea Pharmaceuticals, Inc.
AVIR · Pharmaceutical Preparations
BioXcel Therapeutics, Inc.
BTAIQ · Pharmaceutical Preparations
XTL Biopharmaceuticals Ltd
XTLB · Pharmaceutical Preparations
MAIA Biotechnology, Inc.
MAIA · Pharmaceutical Preparations
Aquestive Therapeutics, Inc.
AQST · Pharmaceutical Preparations
Aquestive Therapeutics is a U.S.-based pharmaceutical company focused on developing and manufacturing medicines that use proprietary delivery technologies to make complex drugs easier to administer.
Last updated: 11/08/2026